Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis

Nivolumab is now a reference treatment for patients with advanced non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. Little data are available on treatment approaches following discontinuation of nivolumab and on the interest of a second course of immunotherapy after nivolumab discontinuation. The aims of this study were to describe treatment pathways following nivolumab discontinuation and to describe survival following retreatment with immunotherapy.

Source: Lung Cancer - December 30, 2019 Category: Cancer & Oncology Authors: Matteo Giaj Levra, Fran çois-Emery Cotte, Romain Corre, Christophe Calvet, Anne-Françoise Gaudin, John R. Penrod, Valentine Grumberg, Baptiste Jouaneton, Ronan Jolivel, Jean-Baptiste Assie, Christos Chouaïd Source Type: research